Alivus Life Sciences AMC Q3 Results 2026 Highlights: Net Profit Rises by 9.71% & Revenue Up 4.84% YoY
Posted by : sachet | Fri Jan 23 2026
Click and Sign Up to Get Live Updates on Q3 Results
Alivus Life Sciences AMC Q3 Results FY26: During Q3 FY26, Alivus Life Sciences AMC’s profit increased 9.71% YoY, while revenue increased by 4.84% YoY. The company posted robust numbers, with Q3 PAT at ₹150.26 crores and revenue at ₹672.89 crores. Alivus Life Sciences AMC showed its Q3 results on 22nd January 2026.
Alivus Life Sciences AMC Q3 Results FY26: Extracts of FY25 & FY26
| Particulars | Standalone Figures | |
| 31st Dec 2025 | 31st Dec 2024 | |
| Revenue from Operations | ₹672.89 | ₹641.84 |
| Profit Before Tax (PBT) | ₹245.20 | ₹200.76 |
| Profit After Tax (PAT) | ₹150.26 | ₹136.96 |
Alivus Life Sciences AMC Q3 Results FY26 Highlights (Q3 FY26 vs FY25)
- Alivus Life Sciences AMC clocked Q3 FY26 standalone revenue of ₹672.89 crores vs ₹641.84 crores.
- On the profit front, Alivus Life Sciences AMC earned a standalone PAT of ₹150.26 crore in Q3 FY26. During FY25, the company’s PAT stood at ₹136.96 crore.
- According to the standalone figures, Alivus Life Sciences AMC’s quarterly PAT increased by 9.71% YoY, while revenue increased by 4.84%.
Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!
Alivus Life Sciences AMC Share Price Performance
On the opening bell on 23rd January 2026, Alivus Life Sciences AMC shares opened at ₹861.95 per share. However, the initial gains have since eroded, and Alivus Life Sciences AMC’s shares are currently trading at ₹877.50 per share, which is lower than the opening price.
Considering the long-term performance, Alivus Life Sciences AMC shares have yielded returns of approximately -24.80% over the past year and -23.65% over the past 5 years. Over the maximum timeframe, Alivus Life Sciences AMC shares delivered a -23.65% return to investors.
What Analysts Expect Post Q3 Results?
Following Alivus Life Sciences AMC’s robust Q3 results for FY26, analysts expect its share price to rise. According to analysts, Alivus Life Sciences AMC’s share price could reach ₹950.00 per share in the coming year and, in a downturn, could hit ₹861.40 per share. However, one must ignore stock market volatility and invest in Alivus Life Sciences AMC’s shares after thorough research.
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Recent Articles
Aritas Vinyl IPO GMP & Subscription Status: Day 2
Related Posts
Bandhan Bank Q3 Results 2026 Highlights: Net Profit Falls by 51.79% & Revenue Down 7.11% YoY
Home First Finance Q3 Results 2026 Highlights: Net Profit Surged by 43.97% & Revenue Up 18.80% YoY
Mphasis Q3 Results 2026 Highlights: Net Profit Rises by 3.36% & Revenue Up 12.39% YoY
Adani Energy Solutions Q3 Results 2026 Highlights: Net Profit Falls by 1.69% & Revenue Up 15.43% YoY
